Johnson & Johnson Medical Devices

Johnson & Johnson’s Medical Devices segment generates roughly $30 billion a year. By every conventional measure, it works. It clears regulators, it passes audits, and it restructures when it needs to. And yet, for twenty-one years, it has produced the same kind of product-safety failure in one product line after another, while never going under and never self-correcting.

QSIA was applied to a single question. Not whether J&J is compliant, and not what it should do, but whether its product-quality architecture is structurally sound: whether the system that produces its devices can sustain what it claims. The analysis used only public-record evidence, including FDA enforcement actions, federal and state litigation, judicial decisions up to the U.S. Supreme Court, and disclosed settlements. It is independent of, and not affiliated with, authorized by, or endorsed by Johnson & Johnson, and it offers no investment advice.

What the public record shows

The same failure shape appears across four unrelated product categories and both divisions.

• Transvaginal mesh (Prolift): entered the market bypassing standard FDA premarket review, was withdrawn after years on sale, and the Supreme Court later upheld a finding that the risks had been concealed.
• Hernia mesh (Physiomesh): higher than expected failure rates, with more than 3,600 claims since resolved.
• DePuy ASR hip: roughly a 13 percent five-year failure rate, internal documents indicating that rate was anticipated, and $4.4 billion in settlements.
• Surgical staplers: a Class 1 recall, the most severe category, with one death. A third Ethicon product line showing the same pattern, surfacing while the earlier cases were still in court.

Meanwhile the original suture line, the business the quality system was actually built for, has run for decades at roughly 70 percent global share with no comparable failures.

The structural finding

That contrast is the diagnosis. The quality architecture works, for sutures. It was never rebuilt for the mesh, orthopedic, and stapler categories that acquisitions and expansion added. QSIA scores five structural dimensions on a fixed scale, and J&J’s composite came to 7 out of 25, with the root located in one place.

• Scope Discipline (2 of 5). The portfolio outgrew the quality system meant to govern it. This is the root.
• Definitional Adequacy (1 of 5) and Influence Transparency (1 of 5). The downstream consequences: products carrying safety identities their real performance did not support, and a documented quality process that bore little resemblance to how correction actually happened. In practice, litigation, not internal systems, forced the withdrawals.
• Justification Grounding (1 of 5). Safety gates that were bypassed, or satisfied on paper while contradicted by the company’s own internal data.
• Verification Depth (2 of 5). Three reorganizations in three years that adapted the governance shell without ever repairing the root.

The structural signature is insulation. Every correction mechanism the organization has, from internal quality review to regulatory clearance to litigation itself, is severed from the level where the failures originate. Financial scale absorbs billions in settlements without ever transmitting the signal that would force a rebuild. In the language of the analysis: the organization can survive its own quality failures, but it cannot prevent them from recurring. It can be made to pay. It cannot be made to hold.

Why this is the demonstration

A clean regulatory record told one story. The structure told another, and the structure was right. Every test passed, and the failures kept coming, precisely where the architecture made them likely.

That is what a QSIA analysis produces. Not a compliance verdict, and not a consultant’s action plan, but a located, scored, evidence-traceable account of where a system is fragile, why it cannot fix itself, and what any repair would have to satisfy to hold.

This summary is the shape of the work.

Drawn entirely from public-record sources. A QSIA engagement is a structural diagnostic, not a legal or financial opinion.